Sign inJoin waitlistJoin the waitlist

Karine Tawagi

Fellowship Program Director · University of Illinois College of Medicine at Chicago

Credentials: · · · · · · ·

History

University of Illinois College of Medicine at Chicago Fellowship
Present
University of Illinois College of Medicine at Chicago
Present

Hematology and Medical Oncology
2018–2021
Internal Medicine
Trinity Health Ann Arbor Hospital
2015–2018
ST GEORGE'S UNIV SCH OF MED, ST GEORGE'S, GRENADA
2011–2015

Research

Timing of steroid initiation and response rates to immune checkpoint inhibitors in metastatic cancer
Journal for ImmunoTherapy of Cancer · 2021 · 86 citations
Concomitant Proton Pump Inhibitors and Outcome of Patients Treated with Nivolumab Alone or Plus Ipilimumab for Advanced Renal Cell Carcinoma
Targeted Oncology · 2022 · 75 citations
Multivariate mortality analyses in COVID-19: Comparing patients with cancer and patients without cancer in Louisiana
Cancer · 2021 · 59 citations

Marc Matrana
5 papers
Diana Maslov
4 papers · 4 as a resident
Victoria Chung
4 papers · 3 as a fellow
IA
Inas Abuali
3 papers
Natalie Reizine
3 papers
RS
Richard Shellenberger
3 papers
RM
Ronak Mistry
3 papers
Samantha Armstrong
3 papers
Zoe Blake
3 papers
Agrima Mian
2 papers · 2 as a fellow
Ahmad Nassar
2 papers · 2 as a fellow
Ahsan Wahab
2 papers

Clinical trials

A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Site PI · Recruiting · Phase 3
Eli Lilly and Company
2025–2033
A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2035